70基因签名检测对雌激素受体阳性早期乳腺癌患者辅助化疗决策的影响:前瞻性队列研究结果
这项前瞻性、观察性、多中心研究纳入660例70岁以下雌激素受体阳性早期乳腺癌术后患者,在70基因签名检测前后询问医生辅助化疗意向。检测前医生对41%患者推荐化疗、16%推荐免除化疗,43%无法确定;检测后51%的初步建议发生改变,最终推荐与检测结果一致率达96%。
要点
- 检测前医生对41%患者推荐化疗,16%推荐免除化疗,43%无法确定。
- 检测后51%的初步建议发生改变,最终推荐与70基因签名结果一致率达96%。
- 初始推荐化疗与不推荐化疗的患者中,分别有56%与59%被70基因签名归为低风险。
核心结论
- 在这项前瞻性多中心研究中,70基因签名检测使半数患者的医生辅助化疗推荐意向发生改变。
研究设计与样本
- 前瞻性、观察性、多中心研究,纳入2013年10月1日至2015年12月31日在33家医院治疗的660例70岁以下雌激素受体阳性早期乳腺癌术后患者。
主要发现
- 51%的患者为pT1cN0、BRII、HER2-Neu阴性乳腺癌。
- 基于常规临床病理特征,医生在660例患者中推荐化疗270例(41%)、推荐免除化疗107例(16%),其余43%的患者医生无法确定建议。
- 初始推荐化疗与不推荐化疗的患者中,分别有56%与59%被70基因签名归为低风险(κ=0.02;95%CI -0.08至0.11)。
- 检测结果公布后,检测前已获建议的患者中51%的初步建议发生改变;医生最终化疗推荐与70基因签名结果一致的患者占96%。
关键数值与推荐
- 荷兰指南建议对无明确淋巴结转移的雌激素受体阳性早期乳腺癌患者使用经过验证的基因表达谱。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Gene-expression profiles increasingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metastases. We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients with ER-positive, early-stage breast cancer. Patients and Methods In a prospective, observational, multicenter study in patients younger than 70 years old who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether they intended to administer adjuvant CT before deployment of the 70-GS test and after the test result was available. Results Between October 1, 2013, and December 31, 2015, 660 patients, treated in 33 hospitals, were enrolled. Fifty-one percent of patients had pT1cN0, BRII, HER2-Neu-negative breast cancer. On the basis of conventional clinicopathological characteristics, physicians recommended CT in 270 (41%) of the 660 patients and recommended withholding CT in 107 (16%) of the 660 patients. For the remaining 43% of patients, the physicians were unsure and unable to give advice before 70-GS testing. In patients for whom CT was initially recommended or not recommended, 56% and 59%, respectively, were assigned to a low-risk profile by the 70-GS (κ, 0.02; 95% CI, -0.08 to 0.11). After disclosure of the 70-GS test result, the preliminary advice was changed in 51% of patients who received a recommendation before testing; the definitive CT recommendation of the physician was in line with the 70-GS result in 96% of patients. Conclusion In this prospective, multicenter study in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physician-intended recommendation to administer CT in half of the patients.
引用
- Kuijer A, Straver M, den Dekker B, et al. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study. J Clin Oncol. 2017. PMID: 28813638. doi:10.1200/JCO.2016.70.3959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。